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RIG-I, a virus sensor that triggers innate antiviral
response, is a DExD/H box RNA helicase bearing
structural similarity with Dicer, an RNase III-type
nuclease that mediates RNA interference. Dicer
requires double-stranded RNA-binding protein part-
ners, such as PACT, for optimal activity. Here we
show that PACT physically binds to the C-terminal
repression domain of RIG-I and potently stimulates
RIG-I-induced type I interferon production. PACT
potentiates the activation of RIG-I by poly(I:C) of
intermediate length. PACT also cooperates with
RIG-I to sustain the activation of antiviral defense.
Depletion of PACT substantially attenuates viral
induction of interferons. The activation of RIG-I by
PACT does not require double-stranded RNA-
dependent protein kinase or Dicer, but is mediated
by a direct interaction that leads to stimulation of
its ATPase activity. Our findings reveal PACT as an
important component in initiating and sustaining
the RIG-I-dependent antiviral response.
INTRODUCTION
Host cells sense invading viruses and mobilize innate immune
response to counteract their infection. Detection of viral nucleic
acids by the cytoplasmic sensor RIG-I generates an activation
signal which leads ultimately to the production of type I inter-
ferons (IFNs) that are important effectors in innate immunity
(Yoneyama et al., 2004). RIG-I discriminates between viral and
cellular RNAs by recognizing 50-triphosphates and base-paired
structures (Hornung et al., 2006; Pichlmair et al., 2006; Schlee
et al., 2009b; Schmidt et al., 2009). On the other hand, RIG-I
senses viral DNA in the cytosol (Choi et al., 2009) through
multiple mechanisms, including the recognition of 50-triphos-
phate RNA generated from DNA template by RNA polymerase
III (Chiu et al., 2009). However, some double-stranded RNAs
without 50-triphosphates can also activate RIG-I (Hausmann
et al., 2008; Schlee et al., 2009a). RIG-I is most efficiently acti-
vated by viruses, but the nature of viral RNA agonists bound toCellendogenous RIG-I during the course of infection has not been
unequivocally determined (Baum et al., 2010; Rehwinkel et al.,
2010). RIG-I is activated potently by unattached polyubiquitin
chains (Zeng et al., 2010), but the physiological inducers of this
activation are not understood. It also remains to be seen whether
the action of RIG-I might require additional cellular partners and
modifiers.
RIG-I is a DExD/H box RNA helicase bearing significant struc-
tural similarity with Dicer, an RNase III-type nuclease required for
RNA interference (RNAi). Human Dicer requires dsRNA-binding
protein partners TRBP and PACT for optimal activity in RNAi
(Chendrimada et al., 2005; Haase et al., 2005; Lee et al., 2006;
Kok et al., 2007). Surprisingly, a C. elegans protein named
p110, which is an unrecognized homolog of RIG-I, was found
to interact physically with PACT homolog RDE4 in an early study
(Tabara et al., 2002). In addition, before the identification of
RIG-I, PACT was also known to be capable of stimulating viral
induction of type I IFNs (Iwamura et al., 2001). These findings
prompted us to examine the interaction between human RIG-I
and PACT as well as the implications in innate antiviral response.
RESULTS
PACT Interacts with RIG-I
We employed two different approaches to investigate the inter-
action of PACT andRIG-I. First, we performed coimmunoprecipi-
tation experiments with lysates of transfected and untransfected
HEK293 cells. For transfected cells expressing Myc-PACT and
Flag-RIG-I, both proteinswere found in the precipitates prepared
separately with anti-Myc and anti-Flag (Figure 1A, lanes 2 and 3
compared to lane 1), and the formation of a RIG-I-PACT protein
complex inside cells was confirmed. In contrast, Myc-PACT did
not form a complex with Flag-TRAF3 (Figure 1A, lane 3), lending
further support to the specificity of the interaction between PACT
and RIG-I. Interestingly, only a fraction of RIG-I was seen to be
associated with PACT. Likewise, only a subset of PACT bound
to RIG-I. These results were compatible with the notion that the
two multifunctional proteins might form functional complexes
with other partners (Yoneyama et al., 2004; Kok et al., 2007).
When we repeated the coimmunoprecipitation experiment
using mock-transfected and mock-infected A549 cells, RIG-I
was not detected in either anti-PACT or anti-RIG-I precipitate
(Figure 1B, lanes 2 and 3), indicating that the amount of RIG-I
was too low in these cells. After induction of RIG-I expressionHost & Microbe 9, 299–309, April 21, 2011 ª2011 Elsevier Inc. 299
Figure 1. PACT Directly Interacts with RIG-I
(A) RIG-I and PACT were coimmunoprecipitated from lysates of transfected
HEK293T cells. Cells were transfected with the indicated combinations of
Myc-PACT, Flag-RIG-I, and Flag-TRAF3 expression plasmids. Reciprocal
immunoprecipitation (IP) and western blotting (WB) were performed with the
indicated antibodies.
(B) RIG-I and PACT were coimmunoprecipitated from lysates of untransfected
A459 cells. Cells were mock infected or infected with 80 HA units of SeV for
24 hr. Immunoprecipitation was performed with the indicated antibodies.
Endogenous PACT and RIG-I in the precipitates were probed with anti-PACT
and anti-RIG-I.
(C) GST pull-down assay. GST-RIG-I and V5/His-PACT proteins purified to
homogeneity were incubated for 1 hr and bound to glutathione beads. Bound
proteins were analyzed with anti-His (upper panel) and anti-GST (lower panel).
(D) PACT binds to CTD of RIG-I. GST pull-down assay was performed with
PACT and truncated mutants of RIG-I. The upper diagram depicts the domain
organization of truncated mutants. Results are representative of three inde-
pendent experiments.
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tate (Figure 1B, lane 5), and reciprocally, PACT was detected in
the anti-RIG-I precipitate (Figure 1B, lane 6). Thus, endogenous
PACT forms a complex with endogenous RIG-I in virus-infected
cells.300 Cell Host & Microbe 9, 299–309, April 21, 2011 ª2011 Elsevier InNext, to rule out the possibility that the interaction between
RIG-I and PACT is adapted through another protein, we carried
out GST pull-down assay in vitro with purified recombinant
proteins. His-PACT and GST-RIG-I proteins were expressed in
the baculovirus-insect cell system and purified to homogeneity
(see Figure S1 available online). Retention of purified His-PACT
in the glutathione beads bound to purified GST-RIG-I (Figure 1C,
lane 2) indicated a direct interaction between the two entities.
Further analysis with truncated GST-RIG-I mutants revealed
that the C-terminal repression domain (CTD) of RIG-I was suffi-
cient for binding with PACT (Figure 1D, lane 10 compared to
lanes 7–9 and 11), whereas the CARD and helicase domains
were dispensable for this interaction. Nonspecific binding of
GST to PACT was also excluded in light of the inability of
GST-E to interact with PACT (Figure 1D, lanes 5 and 11).
Together, our results confirmed the interaction between RIG-I
and PACT both in cultured cells and in vitro.
PACT Is a Potent Activator of RIG-I
The interaction of PACT with the CTD of RIG-I might plausibly
affect the activation of RIG-I. With this in mind, we went on to
characterize the influence of PACT on RIG-I-induced activation
of IFN-b production in HEK293 cells in which the expression of
endogenous RIG-I was undetectable. We noted that enforced
expression of PACT alone had no influence on the activity of
IFN-b promoter (Figure 2A, bars 2–4). In contrast, coexpression
of RIG-I and PACT resulted in substantial enhancement of RIG-I-
induced activation of IFN-b promoter (Figure 2A, bars 6–8). The
helicase activity of RIG-I was seemingly required for the activa-
tion of RIG-I by PACT, since the helicase-dead K270A mutant
of RIG-I (Yoneyama et al., 2004) was not activated by PACT (Fig-
ure 2A, bars 10–12). Similar results were also obtained when
another reporter driven by the IRF3-binding enhancer elements
alone was used (Figure 2B), suggesting that the stimulatory
effect was mediated through activation of IRF3. In further
support of this, the formation of IRF3 dimer, which is the active
form of IRF3, was observed in HEK293 cells expressing both
RIG-I and PACT (Figure 2C, lanes 2 and 3 compared to lanes
1, 4, 5, and 8). Interestingly, IRF3 dimer was also detected
when RIG-I was induced by IFN-b in PACT-expressing
HEK293 cells (Figure 2C, lane 7 compared to lane 6). The stimu-
lation of RIG-I-dependent activation of IRF3 by PACT was highly
specific, since PACT did not potentiate RIG-I-induced activation
of NF-kB (Figure S2A, bars 9–12 compared to bars 1–4 and 5–8).
Notably, we also observed a similar stimulatory effect of PACT
on MDA5- mediated activation of IFN-b promoter and IRF3 (Fig-
ure S2B, bars 1–4 and 5–8), but not on MDA5-inudced activation
of NF-kB (bars 9–12). Although further experiments are required
to fully characterize the impact of PACT onMDA5, our results did
suggest that PACT might target the conserved CTD in RIG-I and
MDA5. Consistent with the binding of PACT to the CTD of RIG-I
(Figure 1C), PACT had no effect on RIG-IN containing the
N-terminal CARD domain alone (Figure S2C, bars 5–8 compared
to bars 9–12). Finally, facilitation of RIG-I-activated IFN produc-
tion by PACT was also shown by direct measurement of the anti-
viral activity of IFNs. Only in HEK293 cells expressing both RIG-I
and PACT, a large amount of IFNwas produced leading to signif-
icant inhibition (104-fold less virus) of subsequent infection by a
green fluorescent protein (GFP)-expressing vesicular stomatitisc.
Figure 2. PACT Augments RIG-I-Induced
Activation of IFN Production
(A and B) PACT enhances RIG-I-mediated acti-
vation of IFN-b promoter and IRF3. HEK293 cells
were transfected with the indicated reporter and
increasing amounts of PACT expression plasmid
(50, 75, and 100 ng). Dual luciferase assay was
carried out. Results represent three independent
experiments, and error bars indicate SD.
(C) PACT stimulates RIG-I-induced dimerization
of IRF3. HEK293 cells were transfected with
expression plasmids for the indicated proteins. In
lanes 2 and 3, two different doses of PACT were
used. In lanes 5 and 8, constitutively active RIG-IN
and IRF3-5D served as positive controls (Zhang
et al., 2009). In lanes 6 and 7, transfected cells
expressing PACT were either mock treated or
treated with 1000 U/ml IFN-b. Cells were har-
vested at 28 hr posttransfection, and lysates were
analyzed by native gel electrophoresis followed
by western blotting with anti-Myc antibody.
Dimeric and monomeric forms of IRF3 were indi-
cated. The expression of PACT and b-actin was
also verified. Similar results were also obtained
from a duplicate experiment.
(D) PACT stimulates RIG-I-dependent induction of
IFNs. HEK293 cells transfected with the indicated
plasmids were infected at 28 hr posttransfection
with VSV-GFP (moi = 1) for 1 hr. At 16 hr post-
infection, viruses recovered from supernatants
were quantitated by plaque formation assay in
Vero cells. Data in the bar chart represent the
mean ± SD of three independent experiments. *,
the difference between the two groups is statisti-
cally very significant (p = 0.0010) by Student’s t
test.
(E) PACT facilitates viral activation of IFN-b
promoter. At 28 hr posttransfection, HEK293 cells
were infected with 80 HA units of SeV for 1 hr.
Cells were harvested for dual luciferase assay at
10 hr postinfection. Data represent themean ± SD
of three independent experiments. * and **, the
differences between the two groups are statisti-
cally significant (p = 0.0016 and p = 0.011,
respectively) by Student’s t test.
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in the other three groups because plenty of virus was recovered
in the plaque formation assay (Figure 2D, panels/bars 1, 2, and 4
compared to panel/bar 3). Collectively, our data suggested that
PACT exerts a stimulatory effect on the IFN-inducing activity of
RIG-I through an interaction with the CTD.
We also assessed PACT-mediated potentiation of RIG-I
activity in the context of viral infection. HEK293 cells transfected
with different combinations of RIG-I and PACT plasmids were
infected with SeV, and the IFN-b promoter activities were
compared (Figure 2E). Overexpression of PACT alone stimulated
viral induction of IFN-b production about 2-fold (Figure 2E, bar 7Cell Host & Microbe 9, 299–3compared to bar 5). This was probably
due to PACT-mediated stimulation of
RIG-I whose expression was induced
during viral infection (Yoneyama et al.,
2004). Overexpression of RIG-I alonepotentiated viral activation of IFN-b promoter to a similar magni-
tude as in the presence of both PACT and RIG-I (Figure 2E, bar 6
compared to bar 4). PACT was also found to further augment
RIG-I-induced activation of IFN-b promoter in virus-infected
cells (Figure 2E, bar 8 compared to bar 6). These results demon-
strated the cooperation between RIG-I and PACT in the activa-
tion of innate antiviral response in the context of SeV infection.
To shed light on the downstream effectors that transmit the
activation signal triggered by PACT and RIG-I, we used a preva-
lidated siRNA to deplete the transcript of mitochondrial protein
VISA, also known as MAVS or IPS1, which relays RIG-I signaling
to IRF3 and NF-kB (Nakhaei et al., 2009). The effect of PACT and09, April 21, 2011 ª2011 Elsevier Inc. 301
Figure 3. Silencing of PACT Inhibits Viral Induction of IFNs
(A–C) siRNA-transfected A549, IMR90, and MEF cells were infected with
80 HA units of SeV for 1 hr and harvested at different time points. siHCV is an
irrelevant siRNA. Results are representative of three independent experiments,
and error bars indicate SD; h.p.i., hours postinfection.
(D) Endogenous PACT protein in siRNA-transfected HEK293, A549, IMR90,
and MEF cells was analyzed by western blotting at 72 hr posttransfection.
(E) siRNA-transfected A549, IMR90, and MEF cells were infected with
80 HA units of SeV at 72 hr posttransfection. At 1 hr postinfection, culture
medium was transferred into untreated A549, IMR90, and MEF cells and
incubated for another 1 hr. Cells were then infected with VSV-GFP (moi = 1) for
1 hr and analyzed by light and fluorescencemicroscopy at 12 hr after VSV-GFP
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302 Cell Host & Microbe 9, 299–309, April 21, 2011 ª2011 Elsevier InRIG-I on IFN production, as indicated by reporter expression
driven by IFN-b promoter or IRF3-binding enhancer elements,
was substantially attenuated in VISA-depleted cells (Figure S2D,
bars 3–4 compared to bars 1–2, and bars 7–8 compared to bars
5–6). This suggested the requirement of VISA for the activation of
IFN-b production by PACT and RIG-I. Because different VISA-
containing complexes might be used to activate IRF3 and
NF-kB (Poeck et al., 2010), we checked for the recruitment of
downstream effectors using coimmunoprecipitation. We found
that a significant amount of endogenous TBK1 was recruited
to the VISA complex in cells expressing PACT and RIG-I,
whereas VISA-associated CARD9 was barely detectable in the
same cells (Figure S2E, lane 2 compared to lane 1). In contrast,
infection with SeV caused the recruitment of both TBK1 and
CARD9 to the VISA complex (Figure S2E, lane 3) as expected.
This indicated that TBK1 and CARD9were differentially recruited
to the VISA complex in cells expressing PACT and RIG-I.
Because these two proteins are, respectively, required for IRF3
and NF-kB activation (Poeck et al., 2010), this might explain
the specific effect of PACT on IRF3, but not NF-KB (Figure S2A).
We next investigated the role of PACT in viral induction of
IFN-b using RNAi technology. Five siRNAs targeting human or
mouse PACT transcript (siPACTs) were synthesized and intro-
duced into two different cell lines, A549 and IMR90, as well as
primary mouse embryonic fibroblasts (MEFs) (Figures 3A–3C).
Compared to HEK293 cells, A549 cells abundantly expressed
PACT protein (Figure 3D, lane 1 compared to lane 0). Whereas
A549 is a lung adenocarcinoma epithelial cell line, IMR90 cells
are normal diploid lung fibroblasts and MEF are primary cells
derived from mouse embryo. The silencing effects of siPACTs
in A549, IMR90, and MEF cells were verified by western blotting
(Figure 3D). All five siPACTs were found to be highly effective and
specific in counteracting PACT expression in human and mouse
cells (Figure 3D, lanes 2–4, 6–8, and 10–11 compared to lanes 1,
5, and 9, respectively). In line with this almost complete knock-
down of PACT, the induction of IFN-b promoter by SeV was
significantly reduced at all three time points in siPACT-trans-
fected A549, IMR90, and MEF cells (Figures 3A–3C). Consistent
with this, transfer of culture medium from SeV-infected A549,
IMR90, and MEF cells harboring siPACT into fresh untreated
A549, IMR90, and MEF cells resulted in increased infectibility
by VSV-GFP (Figure 3E, bars 2–4, 6–8, and 10–11 compared to
bars 1, 5, and 9, respectively; also see Figure S3A for represen-
tative images, panels 6, 10, and 14 compared to panel 2, and
panels 8, 12, and 16 compared to panel 4), indicative of an inhi-
bition in IFN production. Consistently, when PACT was compro-
mised, the ISRE-dependent transcriptional activity driving the
expression of IFN-stimulated genes was also dampened, but in
a delayed pattern (Figure S3B). In contrast, silencing of PACT
had no influence on viral activation of NF-kB (Figure S3C). Direct
measurement of the steady-state amounts of IFN-b and ISG15
transcripts in PACT-comprised A549 and MEF cells by quantita-
tive RT-PCR confirmed an inhibition of viral activation of IFN-b
and ISG15 (Figures S3D–S3G). These results consistentlyinfection (representative images are shown in Figure S3A). VSV titer was
expressed as arbitrary units reflecting relative intensities of GFP fluorescence.
Data presented represent the mean ± SD of three independent experiments.
c.
Figure 4. PACT-Mediated Activation of RIG-I Requires neither Dicer nor PKR
(A) A549 cells were transfectedwith siGFP or siDicer (Kok et al., 2007). Cells were infectedwith SeV (80 HA unit) for 1 hr. Dual luciferase assay was performed as in
Figure 2. Dicer knockdown was verified by western blotting. *, the difference between the two groups is statistically insignificant (p = 0.42) by Student’s t test.
(B) HEK293 cells were transfected with the indicated expression plasmids and siRNAs. Dual luciferase assay was carried out as in Figure 2. Dicer protein
expression was verified by western blotting. Results are representative of three independent experiments and error bars indicate SD; *, the differences between
the two groups are statistically insignificant (p = 0.64) by Student’s t test.
(C) HEK293 cells were transfected with expression plasmid for PACT or its S246Amutant incapable of activating PKR (Peters et al., 2009a). Dual luciferase assay
was carried out as in Figure 2. Protein expression was verified by western blotting. Results are representative of three independent experiments. *, the difference
between the two groups is statistically insignificant (p = 0.085) by Student’s t test.
(D) HEK293 cells were transfected with the indicated expression plasmids and siRNAs. Dual luciferase assay was carried out as in Figure 2. PKR protein
expression was verified by western blotting. Results are representative of three independent experiments, and error bars indicate SD; * and **, the differences
between the two groups are statistically insignificant (p = 0.69 and p = 0.62, respectively) by Student’s t test.
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Figure 5. PACT Activates RIG-I Independently of 50-Triphosphate
RNA
(A) PACT does not potentiate 50-triphosphate RNA-induced activation of RIG-I.
HEK293 cells were transfected with the indicated expression plasmids and
50-triphosphate RNA. Dual luciferase assay was performed as in Figure 2.
Results represent the mean ± SD of three independent experiments. LMW
pI:C, low-molecular-weight poly(I:C) of 0.2–1 kb in length. * and **, the differ-
ences between the two groups are statistically insignificant (p = 0.70 and
p = 0.84, respectively) by Student’s t test. ***, the difference between the two
groups is statistically significant (p = 0.04) by Student’s t test.
(B) PACT stimulates ATPase activity of RIG-I. Purified recombinant RIG-I
protein (100 ng) was incubated with in vitro-transcribed pppRNA1 (100 ng) or
purified recombinant PACT protein (100 ng) for 25 min at 37C. The mixtures
were further incubatedwith a reaction buffer containing 500 mMof [g-32P]-ATP.
Reaction mixtures were quenched by adding formic acid at the indicated time
points. Samples were resolved by thin-layer chromatography. Experiments
were repeated for three times with similar results.
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PACT Is an Activator of RIG-I in Antiviral Responsesupported the requirement of PACT for full activation of innate
antiviral response during viral infection.
PACT-Mediated Activation of RIG-I Does Not Require
PKR or Dicer
PACT was initially cloned as a cellular binding partner and
protein activator of dsRNA-dependent kinase PKR (Patel
and Sen, 1998). On the other hand, PACT also interacted304 Cell Host & Microbe 9, 299–309, April 21, 2011 ª2011 Elsevier Inwith and stimulated Dicer (Lee et al., 2006; Kok et al., 2007).
While PKR was recently shown to enhance RIG-I-dependent
activation of IFN production (McAllister and Samuel, 2009)
and to modulate IFN mRNA stability in response to some
viruses (Schulz et al., 2010), Drosophila Dicer-2 was also
required for antiviral response (Deddouche et al., 2008). Thus,
it would be of interest to investigate whether PACT-induced
activation of RIG-I is mediated through PKR and Dicer. To
determine the requirement for Dicer, we used siDicer to knock-
down Dicer expression in SeV-infected cells. The specificity
and effectiveness of this siDicer have been validated previously
(Hutva´gner et al., 2001). Since depletion of Dicer did not have
a significant impact on SeV-induced activation of IFN-b produc-
tion (Figure 4A, bar 4 compared to bar 3), which is dependent
on RIG-I and PACT, Dicer unlikely played an important role in
PACT-mediated regulation of antiviral response. Direct analysis
of PACT-dependent activation of RIG-I in Dicer-depleted cells
confirmed that Dicer is dispensable for the ability of PACT to
stimulate RIG-I activity (Figure 4B, bar 6 compared to bars
2 and 4).
On the other hand, we made use of PACT mutant S246A
defective for PKR activation (Peters et al., 2009a) to investigate
the essentiality of PKR in PACT-induced activation of RIG-I.
We noted that the S246A mutant exhibited RIG-I-activating
activity comparable to wild-type PACT (Figure 4C, bar 8
compared to bar 4). In addition, when we used siPKR to knock
down PKR expression (Figure 4D, lanes 5–8 compared to lanes
1–4), PACT-mediated activation of RIG-I was not affected (Fig-
ure 4D, bars 6 and 8 compared to bar 4). Hence, PKR was
unlikely involved in the activation of RIG-I by PACT.
PACT Stimulates ATPase Activity of RIG-I
PACT binds directly to the CTD of RIG-I which is also activated
upon binding with 50-triphosphate dsRNA (Cui et al., 2008).
Because PACT can bind to PKR and activate it in a dsRNA-inde-
pendent fashion (Patel and Sen, 1998), we asked whether PACT
might activate the activity of RIG-I in a similar manner. Indeed,
when we introduced both PACT and 50-triphosphate RNA
agonist of RIG-I into HEK293 cells, an augmentation of IFN
promoter activity was not observed (Figure 5A, bar 5 compared
to bar 4, and bar 7 compared to bar 6). Interestingly, PACT was
found to potentiate the activation of RIG-I by poly(I:C) of 0.2–1 kb
in length (Figure 5A, bar 9 compared to bar 8). This intermediate-
length poly(I:C) without 50-triphosphate was previously known to
be a potent activator of RIG-I (Schlee et al., 2009a), but the
mechanism for its recognition by RIG-I remains elusive. The
enhancement of its activation of RIG-I by PACT suggested that
PACT might augment RNA activation of RIG-I in a 50-triphos-
phate-independent manner. Consistent with the results of lucif-
erase assay, incubation of purified recombinant proteins RIG-I
and PACT in vitro led directly to activation of the intrinsic
ATPase activity of RIG-I in the absence of 50-triphosphate RNA
(Figure 5B, lanes 11–15). In the same assay, 50-triphosphate
dsRNAwas also capable of stimulating RIG-I ATPase (Figure 5B,
lanes 6–10). We were not able to observe any synergistic RIG-I-
stimulating effect between 50-triphosphate RNA and PACT in our
experimental setting (data not shown). Our results indicated that
direct binding of PACT to the CTD of RIG-I sufficiently activated
the virus sensor.c.
Figure 6. PACT Is Required for Signal Amplification in Antiviral Response
(A) HEK293 cell stably expressing PACT (293PACT) or not (293) were treated with IFN-b (1000 U/ml), harvested, and analyzed by dual luciferase assay.
(B) HEK293 cells were grown on transwells and then infected with SeV for 1 hr. After three washes, transwells were placed into the reporter-transfected 293 and
293PACT cells. Cells were incubated for the indicated duration, harvested, and analyzed by dual luciferase assay. Results are representative of three independent
experiments, and error bars indicate SD.
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Response
The activation of RIG-I by PACT in the absence of dsRNApromp-
ted us to investigatewhether PACTmight play a role in amplifying
the activation signal in innate antiviral response in uninfected
cells adjacent to virus-infected cells. To this end, we treated
HEK293 cells stably overexpressing PACT (293PACT) with
IFN-b and followed the activation of IFN-b promoter in these
cells. IFN-b is known to induce various IFN-stimulated genes
includingRIG-I (Yoneyama et al., 2004), which constitutes a posi-
tive feedback loop in the activation of IFN production. We found
that IFN-b production was significantly activated only in IFN-
b-treated 293PACT cells, but not in IFN-b-treated HEK293 cells
(Figure 6A). Accordingly, we noted that the active IRF3 dimer
was detected only in IFN-b-treated 293PACT cells, but not in
IFN-b-treated HEK293 cells (Figure 2C, lane 7 compared to
lane 6). Generally consistent with previous findings (Marie´
et al., 1998; Honda et al., 2006), our results suggested that induc-
tion of RIG-I alone by IFN-bwas not sufficient for full activation of
IFN production. Similar observations were also made if we grew
SeV-infected HEK293 cells on transwells, which are transferable
tissue culture inserts, and then placed them into uninfected
PACT-expressing reporter cells (Figure 6B). Together, our data
supported the notion that PACT is required for IFN-induced acti-
vation of IFN production in neighboring uninfected cells. In other
words, PACT is an essential component in a positive feedback
loop, and it cooperates with RIG-I to sustain the innate antiviral
response.
One related question concerns the activation of PACT expres-
sion, which might be important in antiviral response. Particularly,
it is of interest to seewhether the expression of PACT is transcrip-
tionally induced by RIG-I, IFN-b, or viral infection. To address this
issue, we cloned the PACT promoter and assessed its responseCellto RIG-IN or IRF3 (Figure S4A). Whereas both RIG-IN and IRF3
potently activated IFN-b promoter, they had minimal effect on
the promoter of PACT. Unlike RIG-I and ISG15, whose expres-
sion was significantly induced by IFN-b or SeV infection, the
steady-state levels of PACT mRNA and protein remained
unchanged in IFN-treated or SeV-infected cells (Figures S4B
and S4C). Thus, PACT expression was not induced by IFNs or
viral infection. Taken together, PACT plays a role in initiating
and sustaining RIG-I-induced antiviral response in both infected
anduninfectedcells (Figure 7). Plausibly, PACTmight benaturally
activated in uninfected cells through an as-yet-unknownmecha-
nism. This activation effect was mimicked by the overexpression
of PACT in our experiments presented in Figure 6.
DISCUSSION
In this study, we characterized dsRNA-binding protein PACT
to be a binding partner and potent activator of DExD/H box heli-
case RIG-I (Figures 1 and 2). RNAi depletion of PACT led to inhi-
bition of virus-induced and RIG-I-dependent activation of IFN
production (Figure 3). The stimulation of RIG-I by PACT did not
require PKR or Dicer (Figure 4), but was mediated through
a direct interaction with the CTD of RIG-I leading to activation
of ATPase activity (Figure 5) and plausibly a conformational
change associated with the recruitment of downstream effec-
tors. PACT facilitated RNA activation of RIG-I in a 50-triphos-
phate-independent manner (Figure 5). PACT activation of RIG-I
is also required for amplification of activation signal in innate
immunity (Figures 6 and 7).
Our work identified another component in innate antiviral
response. This is consistent with the finding that PACT stimu-
lated viral induction of IFN-b (Iwamura et al., 2001). In addition,
previous RNAi knockdown experiments in mice also suggestedHost & Microbe 9, 299–309, April 21, 2011 ª2011 Elsevier Inc. 305
Figure 7. A Working Model for the Role of PACT in Initiating and Sustaining RIG-I-Induced Antiviral Response
IFNAR, IFN-a/b receptor. PACT might be activated through an as-yet-unknown mechanism in uninfected cells.
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kines and viral infection (Bennett et al., 2006). Pact knockout in
mice created by one group through complete deletion of coding
sequence turned out to be lethal (Bennett et al., 2008). In
contrast, Pact null mice made by another group through removal
of exon 8 coding for C-terminal of PACT showed developmental
defects in hearing and pituitary function (Rowe et al., 2006;
Peters et al., 2009b), but it remains to be clarified whether a trun-
cated PACT protein that might be expressed in some tissues and
cells of these mice could be functional, as in the case of
Drosophila homolog of PACT named Loqs-PD (Hartig et al.,
2009; Zhou et al., 2009). In this connection, further analyses
are required to elucidate the physiological function of PACT in
innate immunity and RNAi in animal model.
Although enzymatically inactive RIG-I was previously demon-
strated to be able to activate IFN production (Bamming and
Horvath, 2009), RIG-I is a ligand-dependent ATPase, and the
ATPase activity was shown to be required for RNA-induced
conformational change of RIG-I (Takahasi et al., 2008) and sensi-
tization of RIG-I for further activation by unattached polyubiquitin
chains (Zeng et al., 2010). Intriguingly, the unattached polyubi-
quitin chains can interact with and further activate RIG-IN lacking
the CTD, but they were unable to activate an ATPase-dead
mutant of RIG-I (Zeng et al., 2010). In line with some of these
reports, our finding that PACT can sufficiently activate the
ATPase activity of RIG-I supports the importance of ATPase
activity in RIG-I activation. Further investigations are required
to elucidate whether and how PACT interaction with RIG-I might
affect the conformation of RIG-I or the interaction of the
N-terminal domain of RIG-I with unattached polyubiquitin
chains.
PACT can physically interact with viral antagonists of IFN such
as influenza A virus NS1 (Li et al., 2006) and herpes simplex virus
Us11 (Peters et al., 2002). The crucial role of PACT in facilitating306 Cell Host & Microbe 9, 299–309, April 21, 2011 ª2011 Elsevier InRIG-I-dependent antiviral response suggested that PACT might
serve as another regulatory point on which different viral proteins
converge to circumvent host defense. Further investigations are
underway in our laboratory to elucidate the mechanisms by
which viral proteins inhibit the function of PACT and RIG-I.
A paralog of PACT termed TRBP was originally identified and
characterized by its high affinity for TAR, a hairpin RNA encoded
by human immunodeficiency virus type 1 (Gatignol et al., 1991).
Although both PACT and TRBP bind to PKR and have three
similar dsRNA-binding domains, TRBP exerts an inhibitory effect
on PKR (Park et al., 1994). In sharp contrast, both TRBP and
PACT interact simultaneously with Dicer and are required for
Dicer function in RNAi (Kok et al., 2007). It will be of particularly
great interest to elucidate whether TRBP also interacts with
and modulates RIG-I activity. Our preliminary results suggested
that TRBP neither stimulates RIG-I nor forms a triple complex
with PACT andRIG-I (data not shown). Nevertheless, the interac-
tion of PACT or TRBP with RIG-I and other RIG-I-like virus
sensors, MDA5 and LGP2 (Satoh et al., 2010), merits further
analysis. One emerging concept is that PACT might serve as
a multiuse switch in several dsRNA-dependent signaling path-
ways by engaging different partners. Thus, it is of pivotal impor-
tance to shed light on how PACT interacts with its partners to
coordinate its modulatory function on RIG-I, PKR, and Dicer.
Although PACT could activate RIG-I in vitro in the absence of
RNA (Figure 5), PACT is a dsRNA-binding protein that can bind
to RNA ligands of RIG-I. The RNA-binding properties of PACT,
TRBP, and other related partners of Dicer are influential in Dicer
function (Parker et al., 2008). In support of a role of PACT in
ligand-induced activation of RIG-I, PACT was found to enhance
the activation of RIG-I by intermediate-length poly(I:C) in a 50-
triphosphate-independent manner (Figure 5A). Because PACT
can bind directly to poly(I:C) (Patel and Sen, 1998), it will be of
interest to seewhetherandhowPACTmight selector concentratec.
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MDA5. Compared to known RIG-I agonists including 50-triphos-
phateRNA, virusesactivateRIG-Imuchmorepotently andpersis-
tently (Nakhaei et al., 2009). It is therefore plausible that naturally
occurring agonists of RIG-I generated during the course of viral
infection might be more powerful. However, the identity of these
natural agonists remains controversial (Baum et al., 2010;
Rehwinkel et al., 2010). It is still an open question as to whether
PACTmight recognizeanyof theseagonists other than50-triphos-
phate RNA and facilitate their activation of RIG-I. Our preliminary
analysis of defective interfering RNAs generated during the
course of SeV infection revealed that PACT could potentiate the
activationof IFNproductionbysomeof thesedefective interfering
RNAs (data not shown). Further characterization of the RIG-I
ligands and their interaction with PACT in infected cells might
shed light on themechanism throughwhich PACT stimulates viral
induction of type I IFNs (Figure 2 and Iwamura et al., 2001).
We found that PACT and RIG-I preferentially activate IRF3, but
not NF-kB (Figure S2A). We further correlated PACT-induced
activation of RIG-I with strong recruitment of TBK1, but not
CARD9, to the VISA-containing complex (Figure S2E). Our find-
ings are consistent with the notion that RIG-I signaling might
bifurcate or trifurcate at the level of VISA complex formation
(Poeck et al., 2010). Although VISA is required for both IRF3
and NF-kB activation, it is not too surprising that upstream
signals might selectively induce the formation of particular
VISA-containing complex to impinge on IRF3 only. Some activa-
tors of RIG-I and VISA signaling, such as DDX3 and mitofusin 1,
are actually not known to activate NF-kB (Schro¨der et al., 2008;
Onoguchi et al., 2010). Exactly how PACT and other signals fine-
tune the activity of RIG-I leading to differential activation of IRF3
and NF-kB remains to be elucidated.
EXPERIMENTAL PROCEDURES
Plasmids
Expression plasmid for Flag-RIG-I (pEF-flagRIG-I) and reporter construct
pIFN-b-Luc were kindly provided by Takashi Fujita (Yoneyama et al., 2004).
RIG-IN expression plasmid was constructed by PCR subcloning a DNA frag-
ment encoding the N-terminal CARD region (1–284 amino acids) of RIG-I
into pCMVtag2B vector (Stratagene). Myc-PACT expression plasmid has
been described (Kok et al., 2007). pIRF3-Luc contains three tandem copies
of the IRF3-binding site in IFN-b promoter. Baculoviral transfer vector
pAcGHLT expressing full-length RIG-I was provided by Takashi Fujita (Cui
et al., 2008). RIG-I-truncated mutants B-E comprise amino acids 258–926,
606–926, 742–926, and 1–741, respectively (Figure 1C). p3800-Luc reporter
was constructed by inserting a PCR fragment containing the PACT promoter
region (3800 to +1) into pGL3.
Antibodies
Antibodies used in immunoprecipitation were mouse anti-Flag (M2; Sigma),
mouse anti-Myc (9E10; Roche), and mouse anti-VISA (E3; Santa-Cruz). Anti-
bodies for western blotting included mouse anti-Flag (M5; Sigma), rabbit
anti-Myc (A-14; Santa Cruz), mouse anti-GST (B-14; Santa Cruz), mouse
anti-V5 (Invitrogen), mouse anti-RIG-I (D14G6, Cell Signaling), mouse anti-
TBK1 (108A429, Enzo), rabbit anti-Dicer (H-212; Santa Cruz), and rabbit
anti-CARD9 (Enzo).
Protein and RNA Analysis
Western blotting, immunoprecipitation, GST pull-down assay, dual luciferase
reporter assay, fluorescence microscopy, and RT-PCR were performed as
described (Kok and Jin, 2006; Kok et al., 2007). Quantitative real-time PCR
was carried out in StepOne Real-Time PCR System (Applied Biosystems).CellQuantitation of target mRNA expression was achieved with the comparative
Ctmethod. Relative expression level of targetmRNAwas calculated from2-DCt.
Viral Infection and Plaque Formation Assay
HEK293, A549, Vero, IMR90, and MEF cells were cultured as described (Kok
et al., 2007; Siu et al., 2009). Primary MEF cells were generated from E13
embryos of wild-type mouse in C57BL/6J background. SeV (Cantell strain)
was purchased from American Type Culture Collection. In all experiments,
80 HA units of SeV was added to each well in a 12-well plate. GFP version
of vesicular stomatitis virus (VSV-GFP) was kindly provided by Jacques Per-
rault, Brian Lichty, and Dominique Garcin (Ostertag et al., 2007; Brown et al.,
2009). For plaque formation assay, Vero cells were infected with serial
10-fold dilutions of the virus in culture medium. Infected Vero cells were then
overlaid with 1:1 culture medium containing 1% agarose. At 16 hr postinfec-
tion, cells were fixed with 1:1 methanol-ethanol and stained with 0.05% crystal
violet.
RNA Transfection
HEK293, A549, IMR90, and MEF cells were transfected with 50 nM RNA using
Lipofectamine 2000 (Invitrogen). Target sequences of siPACT-1, siPACT-2,
siPACT-3, siPACT-4, siPACT-5, siPKR-1, siPKR-2, siGFP, siDicer, siVISA,
and siHCV were 50-GAGAGAAUAUACUACAAUU-30, 50-GCAGAGGCUGC
CAUAAACA-30, 50-GCCUCCUUAGUAUUCCAAA-30, 50-GAGGGAAUACACC
ACGAUC-30, 50-CACCGAUUCAGGUAUUGCA-30, 50-GACGGAAAGACUUAC
GUUA-30, 50-GGAACUUUGCGAUACAUGA-30, 50-GCAAGCUGACCCUGAAG
UU-30, 50-UGCUUGAAGCAGCUCUGGA-30, 50-CAAGACCUAUAAGUAUAU
C-30, and 50-CCUCGAGGUAGACGUCAGC-30, respectively. pppRNA1 was
a 50-triphosphate dsRNA of 341 bp corresponding to the 50 end of hepatitis
C virus genome. It was prepared by in vitro transcription and annealing as
described (Schlee et al., 2009b). pppRNA2, alternatively named as hp2.2 in
a previous study (Schmidt et al., 2009), was an in vitro-transcribed RNA with
50-triphosphate and base-paired structure. Low-molecular-weight poly(I:C)
with an average size of 0.2–1 kb was purchased from InvivoGen.
Protein Purification
Preparation of baculoviruses and transduction of Sf9 insect cells were per-
formed using the protocols provided by BD Biosciences. GST-RIG-I and
V5/His-PACT were coexpressed in Sf9 cells. Recombinant baculoviruses
were then amplified to obtain a high-titer stock solution, approximately 107
virus particles/ml as measured by plaque assay. For protein expression, Sf9
cells were infected with viruses (moi = 1), and the proteins expressed were
harvested at 3 days postinfection and were purified using glutathione
(Amersham) and nickel (QIAGEN) beads.
ATPase Assay
Recombinant RIG-I protein (100 ng) purified to homogeneity was incubated
with in vitro-transcribed dsRNA (100 ng) prepared as previously described
(Kok et al., 2007) or with purified recombinant PACT protein (100 ng) for
25 min at 37C. The mixtures were further incubated in a reaction buffer con-
taining 500 mM [g-32P]ATP, 50 mM Tris-acetate (pH 6.0), 5 mM dithiothreitol,
and 1.5 mM MgCl2. Reaction mixtures were quenched by adding formic
acid to a final concentration of 1 M at different time points. Samples were
resolved by thin-layer chromatography on polyethyleneimine cellulose F plates
(Merck) in a buffer containing 1 M formic acid and 0.5 M LiCl.
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